Cargando…

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging

SIMPLE SUMMARY: The aim of this study was to correlate primary staging prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) parameters with either prostate final histopathology (pT) or PSMA-immunochemistry (IHC) features in a cohort of high-risk prostat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vetrone, Luigia, Mei, Riccardo, Bianchi, Lorenzo, Giunchi, Francesca, Farolfi, Andrea, Castellucci, Paolo, Droghetti, Matteo, Presutti, Massimiliano, Degiovanni, Alessio, Schiavina, Riccardo, Brunocilla, Eugenio, D’Errico, Antonietta, Fanti, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046634/ https://www.ncbi.nlm.nih.gov/pubmed/36980602 http://dx.doi.org/10.3390/cancers15061716

Ejemplares similares

PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment
por: Bianchi, Lorenzo, et al.
Publicado: (2023)

The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence
por: Bianchi, Lorenzo, et al.
Publicado: (2022)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge
por: Vetrone, Luigia, et al.
Publicado: (2023)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

High Prognostic Value of (68)Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
por: Gasparro, Donatello, et al.
Publicado: (2023)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

In vitro and in vivo comparative study of a novel (68)Ga-labeled PSMA-targeted inhibitor and (68)Ga-PSMA-11
por: Chen, Huanyu, et al.
Publicado: (2021)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
por: Rüschoff, Jan H., et al.
Publicado: (2021)

Automated synthesis and quality control of [(99m)Tc]Tc-PSMA for radioguided surgery (in a [(68)Ga]Ga-PSMA workflow)
por: Aalbersberg, Else A., et al.
Publicado: (2020)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

(68)Ga-PSMA PET-CT and PSMA score affecting therapeutic decision-making in high-risk prostatic carcinoma
por: Yasmin, Tahira, et al.
Publicado: (2023)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

Mild (68)Ga PSMA-11 Uptake in Incidental Pituitary Adenoma
por: Beyhan, Ediz, et al.
Publicado: (2022)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Threshold for defining PSMA-positivity prior to (177)Lu-PSMA therapy: a comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL in metastatic prostate cancer
por: Heilinger, Jan, et al.
Publicado: (2023)

Direct comparison of (99m)Tc-PSMA SPECT/CT and (68)Ga-PSMA PET/CT in patients with prostate cancer
por: Albalooshi, Batool, et al.
Publicado: (2020)

The clinical application of (68)Ga-PSMA PET/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer
por: Pei, Yuchen, et al.
Publicado: (2023)

Automated radiosynthesis of [(68)Ga]Ga‐PSMA‐11 and [(177)Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module for clinical applications
por: Wichmann, Christian W., et al.
Publicado: (2020)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

The Role of [(18)F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [(11)C]Choline PET/CT and Histopathological Analysis
por: Zanoni, Lucia, et al.
Publicado: (2021)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

Impact of external cooling with icepacks on (68)Ga-PSMA uptake in salivary glands
por: van Kalmthout, Ludwike W. M., et al.
Publicado: (2018)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Letter to the Editor: (68)Ga-PSMA-11 for renal cortical PET imaging
por: Sarikaya, Ismet
Publicado: (2022)

A randomised, prospective and head-to-head comparison of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT—Protocol design and rationale
por: Alberts, Ian, et al.
Publicado: (2022)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

Intra-individual dynamic comparison of (18)F-PSMA-11 and (68)Ga-PSMA-11 in LNCaP xenograft bearing mice
por: Piron, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gb19jcg1875p89k5ni99ocklbl